Yam Code

New Paste Browse

https://www.selleckchem.com/products/tiplaxtinin-pai-039.html 002). Median pre- and post-treatment CA-125 levels for LGSC patients were 295.5U/mL and 144U/mL (52% decrease) (p<0.001). The median pre- and post-treatment CA-125 levels for HGSC patients were 767.5 and 35.6 (96% decrease) (p<0.001). For LGSC patients, 4/36 (11%) had partial response (PR), 30/36 (83%) had stable disease (SD), and 2/36 (6%) had progressive disease (PD). In HGSC patients, 27/36 (75%) had PR, and 9/36 (25%) SD. Median PFS for LGSC patients was 18.5months and median OS was 47.4months. This study provides further evidence of relative chemoresistance of LGSC in patients treated with NACT. This study provides further evidence of relative chemoresistance of LGSC in patients treated with NACT. To assess the survival benefit of primary debulking surgery (PDS) compared to interval debulking surgery (IDS) after complete cytoreduction (CC-0) or cytoreduction to minimal residual disease (CC-1) in advanced ovarian cancer. Secondary objective was to evaluate the effect of tumor load and surgical complexity on patients' survival. A retrospective multicentric study was designed, including patients with IIIC-IV FIGO stage ovarian cancer who underwent PDS or IDS with CC-0 or CC-1 from January 2008 to December 2015 in four high-volume institutions. Patients were classified in three groups PDS, IDS after 3-4cycles of neoadjuvant chemotherapy (NACT), and IDS after 6cycles. Disease-free survival (DFS) and overall survival (OS) were estimated. Univariable and multivariable analyses were conducted. We included 549 patients, 175 (31.9%) underwent PDS, 224 (40.8%) had IDS after 3-4cycles of NACT, and 150 (27.3%) underwent IDS after 6cycles. Median DFS in PDS, IDS at 3-4cycles and IDS at 6cycles were 23.0months (95%CI=[20.0-29.3]), 18.0months (95%CI=[15.9-20.0]) and 17.1months (95%CI=[15.0-20.9]), respectively; p<.001. Median OS were 84.0months (95%CI=[68.3-111.0]), 50.7months (95%CI=[44.6-59.5]) and 47.5months (95%

Paste Settings

Paste Title : [Optional]

Paste Folder : [Optional]

Syntax Highlighting : [Optional]

Paste Expiration : [Optional]

Paste Status : [Optional]

Password : [Optional]

Description: [Optional]

Tags: [Optional]

Encrypt Paste (?)

You are currently not logged in, this means you can not edit or delete anything you paste. Sign Up or Login

Paste Settings

Site Languages